Swiftsure International Inc.
Holmes Biopharma, Inc.: $ 1.2 Million Dollar Contract Awarded

Holmes Biopharma Inc. / Contract

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma, Inc.: $ 1.2 Million Dollar Contract Awarded

Scottsdale, Arizona – April 16th, 2008 – Holmes Biopharma, Inc. (Symbol
HHJA Berliner Börse, Sicherheitscode A0KDRX) Holmes Biopharma announces the
recent signing of a $1.2 million dollar contract with a large East Asian
pharmaceutical company.
The contract establishes Holmes Biopharma with another major multinational
pharmaceutical company, generating substantial Phase I clinical trial
revenue for the Omaha operation. Furthermore, this contract is a
significant revenue source for Holmes Biopharma’s Data Management Center in
Toronto, Canada.

'A significant component of this contract is the revenue generated by our
new Data Management Center. We are just beginning to realize the potential
of this highly profitable component of the clinical research business,'
stated John F. Metcalfe President, CEO, Holmes Biopharma Inc.

About Holmes:
Holmes Biopharma Inc. and it’s majority owned subsidiary, Qualia Clinical
Service, Inc. is a contract research organization focused on providing
integrated and cost effective clinical development services. Currently,
clinics operate in Omaha, Nebraska USA, Toronto, Canada. and Kiev, ukraine,
Eastern Europe. For more information about the company
please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors
John F. Metcalfe, President
Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past
performance does not guarantee future results. Readers should consult their
own independent advisers with any investment, including any contemplated
investment. All information contained in this press release should be
independently investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks are not
limited to quarterly fluctuations in results or the companies’ management
of growth and competition. Other risks are detailed in the Company's SEC
filings. Actual results may differ materially from such
information set forth herein.

Contact:
www.holmesbiopharma.com
Tel: 1-800-778-4990 Email: ir@holmesbiopharma.com
8655 East Via De Ventura, G-200, Scottsdale AZ 85258
16.04.2008  Financial News transmitted by DGAP
----------------------------------------------------------------------